Literature DB >> 15363812

Amlodipine increases nitric oxide production in exhaled air during exercise in patients with essential hypertension.

Masayoshi Kato1, Akihiro Matsumoto, Toshiaki Nakajima, Ken Hirose, Kuniaki Iwasawa, Katsu Takenaka, Hiroshi Yamashita, Seiryo Sugiura, Yasunobu Hirata, Ryozo Nagai.   

Abstract

BACKGROUND: Endothelial production of nitric oxide (NO) is attenuated in patients with essential hypertension. We investigated whether treatment with amlodipine increased exhaled NO output (VNO) at rest and during exercise in patients with essential hypertension.
METHODS: We studied the effect of amlodipine in seven untreated hypertensive patients. Cardiopulmonary exercise testing and NO measurement of exhaled air were performed on these patients before and after 2 months of amlodipine treatment.
RESULTS: Amlodipine decreased blood pressure (BP) both at rest and during exercise (at rest: 147.1 +/- 6.4 [SEM]/89.9 +/- 4.4 v 133.6 +/- 5.4/82.7 +/- 3.9 mm Hg, P <.05; at peak exercise: 224.9 +/- 8.0/113.1 +/- 5.3 v 207.0 +/- 6.0/100.7 +/- 5.0 mm Hg, P <.05) without affecting heart rate (at rest: 67.6 +/- 3.9 v 70.4 +/- 4.5 beats/min, P =.33; peak exercise: 146.4 +/- 7.4 v 144.0 +/- 7.2 beats/min, P =.49). Amlodipine did not affect minute ventilation (VE) at rest or during exercise. It did not alter anaerobic threshold, peak oxygen uptake (peak VO(2)), or peak workload. However, after amlodipine treatment, VNO was significantly greater both at rest (130.8 +/- 19.4 v 180.4 +/- 24.8 nL/min, P <.05) and at peak exercise (380.0 +/- 47.5 v 582.6 +/- 74.3 nL/min, P <.05).
CONCLUSIONS: Amlodipine increased NO production, at least in the pulmonary circulation, in patients with essential hypertension. In addition to its antihypertensive effect, the enhancement of NO production by amlodipine in the vasculature of other organs may contribute to its beneficial effects on the cardiovascular system. Copyright 2004 American Journal of Hypertension, Ltd.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15363812     DOI: 10.1016/j.amjhyper.2004.05.025

Source DB:  PubMed          Journal:  Am J Hypertens        ISSN: 0895-7061            Impact factor:   2.689


  4 in total

1.  Antihypertensive efficacy of the oral direct renin inhibitor aliskiren as add-on therapy in patients not responding to amlodipine monotherapy.

Authors:  Waymon Drummond; Mark A Munger; Mohammed Rafique Essop; Mojdeh Maboudian; Mahmudul Khan; Deborah L Keefe
Journal:  J Clin Hypertens (Greenwich)       Date:  2007-10       Impact factor: 3.738

2.  Aliskiren and amlodipine in the management of essential hypertension: meta-analysis of randomized controlled trials.

Authors:  Yukai Liu; Ken Chen; Xun Kou; Yu Han; Lin Zhou; Chunyu Zeng
Journal:  PLoS One       Date:  2013-07-29       Impact factor: 3.240

3.  Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension.

Authors:  Aarti S Mahajan; Rashmi Babbar; Nisheeth Kansal; Satish K Agarwal; Prakash C Ray
Journal:  J Clin Biochem Nutr       Date:  2007-03       Impact factor: 3.114

4.  Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes.

Authors:  Hassan Fares; James J DiNicolantonio; James H O'Keefe; Carl J Lavie
Journal:  Open Heart       Date:  2016-09-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.